drugset / Trial / NCT04132349
Ulipristal Acetate in Symptomatic Uterine Fibroid
NaSingle-groupOpen-labelTreatment
Summary
This study evaluates the effectiveness and safety of ulipristal acetae (UPA) in women with symptomatic uterine fibroids. Those who fulfilled inclusion/exclusion criteria will be treated UPA at daily dose of 5mg.
Timeline
- Start
- 2019-10-23
- Primary completion
- 2020-04-01
- Completion
- 2020-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ulipristal Acetate | Unknown | 5 mg | Oral |